JP5933106B2 - 炭水化物−糖脂質共役ワクチン - Google Patents

炭水化物−糖脂質共役ワクチン Download PDF

Info

Publication number
JP5933106B2
JP5933106B2 JP2015500890A JP2015500890A JP5933106B2 JP 5933106 B2 JP5933106 B2 JP 5933106B2 JP 2015500890 A JP2015500890 A JP 2015500890A JP 2015500890 A JP2015500890 A JP 2015500890A JP 5933106 B2 JP5933106 B2 JP 5933106B2
Authority
JP
Japan
Prior art keywords
carbohydrate
antigen
virus
glucopyranose
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015500890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514067A5 (https=
JP2015514067A (ja
Inventor
ペーター ハー． ゼーベルガー
ペーター ハー． ゼーベルガー
ピエール スタルフォース
ピエール スタルフォース
リベロ ジェンナロ デ
リベロ ジェンナロ デ
マルコ カバラーリ
マルコ カバラーリ
Original Assignee
マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
ユニバーシタットスピタル バーゼル
ユニバーシタットスピタル バーゼル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/002277 external-priority patent/WO2013178236A1/en
Application filed by マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー, マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー, ユニバーシタットスピタル バーゼル, ユニバーシタットスピタル バーゼル filed Critical マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー
Publication of JP2015514067A publication Critical patent/JP2015514067A/ja
Publication of JP2015514067A5 publication Critical patent/JP2015514067A5/ja
Application granted granted Critical
Publication of JP5933106B2 publication Critical patent/JP5933106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015500890A 2012-03-19 2013-03-19 炭水化物−糖脂質共役ワクチン Active JP5933106B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2012/054848 2012-03-19
EP2012054848 2012-03-19
EPPCT/EP2012/002277 2012-05-26
PCT/EP2012/002277 WO2013178236A1 (en) 2012-05-26 2012-05-26 Carbohydrate-glycolipid conjugate vaccines
PCT/EP2013/055719 WO2013139803A1 (en) 2012-03-19 2013-03-19 Carbohydrate-glycolipid conjugate vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016089305A Division JP6235648B2 (ja) 2012-03-19 2016-04-27 炭水化物−糖脂質共役ワクチン

Publications (3)

Publication Number Publication Date
JP2015514067A JP2015514067A (ja) 2015-05-18
JP2015514067A5 JP2015514067A5 (https=) 2015-11-19
JP5933106B2 true JP5933106B2 (ja) 2016-06-08

Family

ID=47901120

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015500890A Active JP5933106B2 (ja) 2012-03-19 2013-03-19 炭水化物−糖脂質共役ワクチン
JP2016089305A Active JP6235648B2 (ja) 2012-03-19 2016-04-27 炭水化物−糖脂質共役ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016089305A Active JP6235648B2 (ja) 2012-03-19 2016-04-27 炭水化物−糖脂質共役ワクチン

Country Status (23)

Country Link
US (1) US10588962B2 (https=)
EP (1) EP2827899B1 (https=)
JP (2) JP5933106B2 (https=)
KR (1) KR101675657B1 (https=)
CN (1) CN104321079A (https=)
AR (1) AR090386A1 (https=)
AU (1) AU2013237497B2 (https=)
BR (1) BR112014023193A2 (https=)
CA (1) CA2866978C (https=)
CY (1) CY1116706T1 (https=)
DK (1) DK2827899T3 (https=)
ES (1) ES2551599T3 (https=)
HK (1) HK1205682A1 (https=)
HU (1) HUE028144T2 (https=)
IL (1) IL234604A (https=)
MX (1) MX337202B (https=)
PL (1) PL2827899T3 (https=)
PT (1) PT2827899E (https=)
RU (1) RU2649009C2 (https=)
SG (1) SG11201405646TA (https=)
SI (1) SI2827899T1 (https=)
TW (1) TWI633112B (https=)
WO (1) WO2013139803A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2851092A1 (en) * 2013-09-18 2015-03-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
WO2016152980A1 (ja) * 2015-03-24 2016-09-29 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法
CN106565800B (zh) * 2015-10-08 2019-08-13 中国人民解放军第二军医大学 三糖对甲氧基苯酚苷类化合物及其制备方法
TWI732825B (zh) * 2016-05-20 2021-07-11 日商王子控股股份有限公司 圖案形成用定向自組裝組成物、圖案形成用定向自組裝組成物用單體及圖案形成方法
CN106620682A (zh) * 2017-01-19 2017-05-10 华中师范大学 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN107955082B (zh) * 2017-12-11 2019-05-10 江南大学 幽门螺旋杆菌脂多糖外核心八糖的制备方法
CN115515965B (zh) * 2020-01-10 2024-12-24 南特大学 新型免疫刺激剂及其在免疫治疗中的用途
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用
KR102915939B1 (ko) * 2024-07-01 2026-01-21 코스맥스에이비 주식회사 피부상재균을 이용한 극성지질 발효물의 제조방법 및 이를 포함하는 화장료 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
FI20010118L (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
WO2006093524A2 (en) * 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
CA2577009C (en) 2004-08-27 2017-05-02 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
GB0419846D0 (en) * 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
WO2007051004A2 (en) * 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
CN102066394B (zh) * 2007-10-12 2015-04-01 路易吉·潘扎 用作免疫佐剂的糖脂的类似物
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
CN102355908B (zh) * 2009-01-23 2014-09-24 德克萨斯大学系统评论委员会 纳米粒子制备的糖脂免疫抗原
US8455565B2 (en) 2011-05-18 2013-06-04 3M Innovative Properties Company Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions

Also Published As

Publication number Publication date
IL234604A (en) 2016-03-31
HK1205682A1 (zh) 2015-12-24
MX337202B (es) 2016-02-17
TW201343662A (zh) 2013-11-01
CA2866978C (en) 2019-01-29
CA2866978A1 (en) 2013-09-26
SG11201405646TA (en) 2014-10-30
US10588962B2 (en) 2020-03-17
KR101675657B1 (ko) 2016-11-11
HUE028144T2 (en) 2016-11-28
MX2014011242A (es) 2015-03-09
EP2827899B1 (en) 2015-08-05
ES2551599T3 (es) 2015-11-20
BR112014023193A2 (pt) 2017-08-01
JP2016183166A (ja) 2016-10-20
WO2013139803A1 (en) 2013-09-26
KR20140138996A (ko) 2014-12-04
RU2649009C2 (ru) 2018-03-29
TWI633112B (zh) 2018-08-21
AR090386A1 (es) 2014-11-05
JP2015514067A (ja) 2015-05-18
DK2827899T3 (en) 2015-10-26
EP2827899A1 (en) 2015-01-28
US20150238597A1 (en) 2015-08-27
SI2827899T1 (sl) 2015-11-30
RU2014142043A (ru) 2016-05-20
PT2827899E (pt) 2015-11-18
AU2013237497A1 (en) 2014-10-02
CN104321079A (zh) 2015-01-28
PL2827899T3 (pl) 2015-12-31
AU2013237497B2 (en) 2016-05-12
CY1116706T1 (el) 2017-03-15
JP6235648B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
JP6235648B2 (ja) 炭水化物−糖脂質共役ワクチン
CA2961694C (en) Vaccines against streptococcus pneumoniae serotype 8
KR102250099B1 (ko) 스트렙토코커스 뉴모니에 1형에 대한 합성 백신
JP2021504439A (ja) クレブシエラ ニューモニエ（Ｋｌｅｂｓｉｅｌｌａ ｐｎｅｕｍｏｎｉａｅ）に対するワクチン
WO2013178236A1 (en) Carbohydrate-glycolipid conjugate vaccines
JP2019504017A (ja) ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型２に対する合成ワクチン
EP3000820A1 (en) Synthetic vaccines against Streptococcus pneumoniae serotype 8
HK1242329B (en) Vaccines against streptococcus pneumoniae serotype 8
HK1242329A1 (en) Vaccines against streptococcus pneumoniae serotype 8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150930

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150930

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20151125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160428

R150 Certificate of patent or registration of utility model

Ref document number: 5933106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250